Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
CAR-T (2)
43 Articles Available
2
2
Can't find what you're looking for? Try our
advanced search
.
Capacity Expansion
Cellectis Moves Forward with Plans for Internal Manufacturing Capability
PAO-M03-19-NI-018
CAR-T
Will CAR-T Therapies be Covered by Medicare?
PAO-M02-19-NI-024
Cell Therapy
Immunotherapy Pioneers a Unveil Updated Efficacy Data of Tisagenlecleucel, plus Checkpoint Inhibitor Research to Boost Response of CAR T-cell Gene Immunotherapy
PR-M12-18-NI-011
CAR-T Therapy
Cellectic CAR-T Therapy Contains Safety Switch and More
PAO-M06-18-NI-017
Janssen Announces Initiation of Phase 1b/2 Clinical Development Program Evaluating JNJ-68284528 CAR-T Cells for the Treatment of Multiple Myeloma
PR-M06-18-NI-005
CAR T
Pfizer and Allogene Therapeutics Form Alliance, Further Developing CAR-T Therapy
PAO-M04-18-NI-015
Immuno-oncology
Allogene Therapeutics Completes Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio
PR-M04-18-NI-40
CAR T
Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio
PR-M04-18-NI-022
CAR-T
bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States
PR-M03-18-NI-107
CAR-T
Pfizer Joins Gilead in CAR-T Development
PAO-M01-18-NI-044
CAR T
Thermo Fisher Gets Key Customer for Its Cell Therapy Activation Reagents
PAO-M01-18-NI-006
Acquisition
Gilead’s new Kite Subsidiary To Buy CAR-T Cell Therapy Company Cell Design Labs
PAO-M01-18-NI-001
Drug Development
ZUMA-1 Study of Yescarta Reports 58% Complete Remission
PAO-M12-17-NI-016
Oncology
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
PR-M12-17-NI-006
CAR T
Mustang Bio Sends CAR T Cell Therapy Line to College
PAO-M11-17-NI-003
CAR-T
Breakthrough CAR-T Immunotherapy Approved
PAO-M10-17-NI-037
Innovation
First-in-Class Cancer Treatment Enters New Era
PAO-M09-17-NI-008
Partnership
Magnetic Bead Technology Activates Novartis’ CAR-T Therapy
PAO-M09-17-NI-007
Acquisition
Gilead Sciences to Fly Kite Pharma for $11.9 Billion
PAO-M08-17-NI-036
«
2
2